Sheets Smith Wealth Management Has $863,000 Position in Amgen Inc. (NASDAQ:AMGN)
Sheets Smith Wealth Management increased its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.1% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,011 shares of the medical research company’s stock after buying an additional 4 shares during the period. Sheets Smith Wealth Management’s holdings in Amgen were worth $863,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently bought and sold shares of the stock. TrimTabs Asset Management LLC boosted its position in Amgen by 88.9% in the first quarter. TrimTabs Asset Management LLC now owns 612 shares of the medical research company’s stock worth $100,000 after buying an additional 288 shares during the last quarter. Alpha Omega Wealth Management LLC boosted its position in Amgen by 19.0% in the first quarter. Alpha Omega Wealth Management LLC now owns 625 shares of the medical research company’s stock worth $103,000 after buying an additional 100 shares during the last quarter. Jackson Grant Investment Advisers Inc. boosted its position in Amgen by 0.6% in the first quarter. Jackson Grant Investment Advisers Inc. now owns 636 shares of the medical research company’s stock worth $104,000 after buying an additional 4 shares during the last quarter. American Beacon Advisors Inc. bought a new position in Amgen during the first quarter worth $106,000. Finally, Nelson Roberts Investment Advisors LLC bought a new position in Amgen during the first quarter worth $121,000. 79.53% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Amgen Inc. (AMGN) traded up 0.10% during midday trading on Tuesday, hitting $174.76. The company’s stock had a trading volume of 636,946 shares. Amgen Inc. has a 12-month low of $133.64 and a 12-month high of $184.21. The firm has a 50-day moving average of $173.04 and a 200 day moving average of $166.70. The firm has a market cap of $127.52 billion, a price-to-earnings ratio of 15.92 and a beta of 1.35.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, July 25th. The medical research company reported $3.27 earnings per share for the quarter, beating the Zacks’ consensus estimate of $3.11 by $0.16. Amgen had a return on equity of 29.85% and a net margin of 35.46%. The business had revenue of $5.81 billion during the quarter, compared to analysts’ expectations of $5.67 billion. During the same period in the previous year, the firm posted $2.84 earnings per share. The company’s revenue was up 2.1% on a year-over-year basis. On average, equities research analysts predict that Amgen Inc. will post $12.57 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 8th. Stockholders of record on Thursday, August 17th will be paid a $1.15 dividend. The ex-dividend date of this dividend is Tuesday, August 15th. This represents a $4.60 dividend on an annualized basis and a dividend yield of 2.63%. Amgen’s payout ratio is presently 41.93%.
WARNING: This piece was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of international copyright & trademark laws. The legal version of this piece can be viewed at https://www.dailypolitical.com/2017/08/08/sheets-smith-wealth-management-has-863000-position-in-amgen-inc-nasdaqamgn.html.
AMGN has been the topic of a number of analyst reports. Oppenheimer Holdings, Inc. set a $189.00 price objective on Amgen and gave the company a “buy” rating in a research report on Tuesday, May 9th. Mizuho set a $195.00 target price on Amgen and gave the company a “buy” rating in a research note on Saturday, May 6th. Cowen and Company reissued a “buy” rating and set a $209.00 target price on shares of Amgen in a research note on Thursday, April 27th. BMO Capital Markets reissued a “buy” rating and set a $198.00 target price (down previously from $200.00) on shares of Amgen in a research note on Monday, May 22nd. Finally, ValuEngine raised Amgen from a “hold” rating to a “buy” rating in a research note on Thursday, July 6th. One research analyst has rated the stock with a sell rating, twelve have given a hold rating, twelve have assigned a buy rating and two have assigned a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $186.64.
In other news, SVP Cynthia M. Patton sold 2,922 shares of Amgen stock in a transaction on Wednesday, May 24th. The stock was sold at an average price of $154.40, for a total value of $451,156.80. Following the completion of the sale, the senior vice president now directly owns 24,214 shares of the company’s stock, valued at $3,738,641.60. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.20% of the company’s stock.
Amgen Company Profile
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.